--- title: Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome nct_id: NCT00296387 overall_status: COMPLETED phase: PHASE3 sponsor: AstraZeneca study_type: INTERVENTIONAL primary_condition: Acute Coronary Syndrome countries: Belgium, Canada, Estonia, France, Greece, Hungary, Ireland, Italy, Portugal, Spain, Tunisia canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00296387.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00296387" ct_last_update_post_date: 2007-12-17 last_seen_at: "2026-05-12T07:25:45.714Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome **Official Title:** Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS **NCT ID:** [NCT00296387](https://clinicaltrials.gov/study/NCT00296387) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE3 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 1160 - **Lead Sponsor:** AstraZeneca - **Conditions:** Acute Coronary Syndrome - **Start Date:** 2006-01 - **Completion Date:** 2007-10 - **CT.gov Last Update:** 2007-12-17 ## Brief Summary The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 75 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion, * Percutaneous coronary intervention (PCI) planned, * Evidence of coronary artery disease Exclusion Criteria: * Hypersensitivity to statins * Any cholesterol lowering medication taken within 1 month prior V1 * Sustained ST-segment elevation on ECG ``` ## Interventions - **Rosuvastatin** (DRUG) - **Atorvastatin** (DRUG) ## Primary Outcomes - **Percentage changes in ApoB/ApoA-I levels** _(time frame: from Day 0 to 3 months)_ ## Secondary Outcomes - **Percentage changes in LDL-C** _(time frame: from Day 0 to 1 month and 3 months)_ - **Percentage changes in the hs-CRP and AUC of hs-CRP levels** _(time frame: from Day -6 to Day 0)_ - **Percentage changes in ApoA-I** _(time frame: from Day 0 to 1 month)_ ## Locations (102) - Research Site, Aalst, Belgium - Research Site, Bonheiden, Belgium - Research Site, Bouge, Belgium - Research Site, Brussels, Belgium - Research Site, Charleroi, Belgium - Research Site, Hasselt, Belgium - Research Site, Huy, Belgium - Research Site, La Louvière, Belgium - Research Site, Leuven, Belgium - Research Site, Edmonton, Alberta, Canada - Research Site, Vancouver, British Columbia, Canada - Research Site, Victoria, British Columbia, Canada - Research Site, Winnipeg, Manitoba, Canada - Research Site, Saint John, New Brunswick, Canada - Research Site, St. John's, Newfoundland and Labrador, Canada - Research Site, Halifax, Nova Scotia, Canada - Research Site, Kingston, Ontario, Canada - Research Site, London, Ontario, Canada - Research Site, Scarborough Village, Ontario, Canada - Research Site, Toronto, Ontario, Canada - Research Site, Laval, Quebec, Canada - Research Site, Montreal, Quebec, Canada - Research Site, Pointe-Claire, Quebec, Canada - Research Site, Saint-Charles-Borromée, Quebec, Canada - Research Site, Sherbrooke, Quebec, Canada - Research Site, Regina, Saskatchewan, Canada - Research Site, Tallinn, Estonia - Research Site, Tartu, Estonia - Research Site, Amiens, France - Research Site, Annecy, France - Research Site, Arras, France - Research Site, Avignon, France - Research Site, Boulogne-Billancourt, France - Research Site, Caen, France - Research Site, Cholet, France - Research Site, Créteil, France - Research Site, Dijon, France - Research Site, Eaubonne, France - Research Site, Évecquemont, France - Research Site, Falaise, France - Research Site, La Roche-sur-Yon, France - Research Site, Lagny-sur-Marne, France - Research Site, Le Coudray, France - Research Site, Le Mans, France - Research Site, Lille, France - Research Site, Marseille, France - Research Site, Metz, France - Research Site, Montpellier, France - Research Site, Nevers, France - Research Site, Paris, France - Research Site, Pau, France - Research Site, Pessac, France - Research Site, Reims, France - Research Site, Rouen, France - Research Site, Saint-Herblain, France - Research Site, Suresnes, France - Research Site, Toulouse, France - Research Site, Tourcoing, France - Research Site, Tours, France - Research Site, Valenciennes, France - Research Site, Vannes, France - Research Site, Villeurbanne, France - Research Site, Athens, Greece - Research Site, Balatonfüred, Hungary - Research Site, Budapest, Hungary - Research Site, Pécs, Hungary - Research Site, Zalaegerszeg, Hungary - Research Site, Dublin, Ireland - Research Site, Galway, Ireland - Research Site, Limerick, Ireland - Research Site, Bari, Apulia, Italy - Research site, Cosenza, Basilicate, Italy - Research Site, Benevento, Campania, Italy - Research Site, Mantua, Lombardy, Italy - Research Site, Rozzano (Milano), Lombardy, Italy - Research Site, Catania, Sicily, Italy - Research Site, Pisa, Tuscany, Italy - Research Site, Perugia, Umbria, Italy - Research Site, Verona, Veneto, Italy - Research Site, Bolzano, Italy - Research Site, Naples, Italy - Research Site, Padova, Italy - Research Site, Roma, Italy - Research Site, Aveiro, Portugal - Research Site, Braga, Portugal - Research Site, Carnaxide, Portugal - Research Site, Faro, Portugal - Research Site, Funchal, Portugal - Research Site, Leiria, Portugal - Research Site, Vila Real, Portugal - Research Site, Zaragoza, Aragon, Spain - Research Site, Toledo, Castille-La Mancha, Spain - Research Site, Tarragona, Catalonia, Spain - Research Site, Fuenlabrada(Madrid), Madrid, Spain - Research site, Madrid, Madrid, Spain - Research Site, Vigo, Pontevedra, Spain - Research Site, Sant Joan d'Alacant, Valencia, Spain - Research Site, Seville, Spain - Research Site, BAB Saâdoun Tunis, Tunisia - Research Site, SIDI Daoud Tunis, Tunisia - Research Site, Sousse, Tunisia - Research Site, Tunis, Tunisia ## Recent Field Changes (last 30 days) - `locations.research site|tunis||tunisia` — added _(2026-05-12)_ - `locations.research site|sousse||tunisia` — added _(2026-05-12)_ - `locations.research site|sidi daoud tunis||tunisia` — added _(2026-05-12)_ - `locations.research site|bab saâdoun tunis||tunisia` — added _(2026-05-12)_ - `locations.research site|seville||spain` — added _(2026-05-12)_ - `locations.research site|sant joan d'alacant|valencia|spain` — added _(2026-05-12)_ - `locations.research site|vigo|pontevedra|spain` — added _(2026-05-12)_ - `locations.research site|madrid|madrid|spain` — added _(2026-05-12)_ - `locations.research site|fuenlabrada(madrid)|madrid|spain` — added _(2026-05-12)_ - `locations.research site|tarragona|catalonia|spain` — added _(2026-05-12)_ - `locations.research site|toledo|castille-la mancha|spain` — added _(2026-05-12)_ - `locations.research site|zaragoza|aragon|spain` — added _(2026-05-12)_ - `locations.research site|vila real||portugal` — added _(2026-05-12)_ - `locations.research site|leiria||portugal` — added _(2026-05-12)_ - `locations.research site|funchal||portugal` — added _(2026-05-12)_ - `locations.research site|faro||portugal` — added _(2026-05-12)_ - `locations.research site|carnaxide||portugal` — added _(2026-05-12)_ - `locations.research site|braga||portugal` — added _(2026-05-12)_ - `locations.research site|aveiro||portugal` — added _(2026-05-12)_ - `locations.research site|roma||italy` — added _(2026-05-12)_ - `locations.research site|padova||italy` — added _(2026-05-12)_ - `locations.research site|naples||italy` — added _(2026-05-12)_ - `locations.research site|bolzano||italy` — added _(2026-05-12)_ - `locations.research site|verona|veneto|italy` — added _(2026-05-12)_ - `locations.research site|perugia|umbria|italy` — added _(2026-05-12)_ - `locations.research site|pisa|tuscany|italy` — added _(2026-05-12)_ - `locations.research site|catania|sicily|italy` — added _(2026-05-12)_ - `locations.research site|rozzano (milano)|lombardy|italy` — added _(2026-05-12)_ - `locations.research site|mantua|lombardy|italy` — added _(2026-05-12)_ - `locations.research site|benevento|campania|italy` — added _(2026-05-12)_ - `locations.research site|cosenza|basilicate|italy` — added _(2026-05-12)_ - `locations.research site|bari|apulia|italy` — added _(2026-05-12)_ - `locations.research site|limerick||ireland` — added _(2026-05-12)_ - `locations.research site|galway||ireland` — added _(2026-05-12)_ - `locations.research site|dublin||ireland` — added _(2026-05-12)_ - `locations.research site|zalaegerszeg||hungary` — added _(2026-05-12)_ - `locations.research site|pécs||hungary` — added _(2026-05-12)_ - `locations.research site|budapest||hungary` — added _(2026-05-12)_ - `locations.research site|balatonfüred||hungary` — added _(2026-05-12)_ - `locations.research site|athens||greece` — added _(2026-05-12)_ - `locations.research site|villeurbanne||france` — added _(2026-05-12)_ - `locations.research site|vannes||france` — added _(2026-05-12)_ - `locations.research site|valenciennes||france` — added _(2026-05-12)_ - `locations.research site|tours||france` — added _(2026-05-12)_ - `locations.research site|tourcoing||france` — added _(2026-05-12)_ - `locations.research site|toulouse||france` — added _(2026-05-12)_ - `locations.research site|suresnes||france` — added _(2026-05-12)_ - `locations.research site|saint-herblain||france` — added _(2026-05-12)_ - `locations.research site|rouen||france` — added _(2026-05-12)_ - `locations.research site|reims||france` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00296387.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00296387* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*